Amazon.com: Science And Human Behavior (9780029290408): B …

').appendTo(flyout.elem());var panelGroup=flyout.getName()+'SubCats';var hideTimeout=null;var sloppyTrigger=createSloppyTrigger($parent);var showParent=function(){if(hideTimeout){clearTimeout(hideTimeout);hideTimeout=null;} if(visible){return;} var height=$('#nav-flyout-shopAll').height(); $parent.css({'height': height});$parent.animate({width:'show'},{duration:200,complete:function(){$parent.css({overflow:'visible'});}});visible=true;};var hideParentNow=function(){$parent.stop().css({overflow:'hidden',display:'none',width:'auto',height:'auto'});panels.hideAll({group:panelGroup});visible=false;if(hideTimeout){clearTimeout(hideTimeout);hideTimeout=null;}};var hideParent=function(){if(!visible){return;} if(hideTimeout){clearTimeout(hideTimeout);hideTimeout=null;} hideTimeout=setTimeout(hideParentNow,10);};flyout.onHide(function(){sloppyTrigger.disable();hideParentNow();this.elem().hide();});var addPanel=function($link,panelKey){var panel=dataPanel({className:'nav-subcat',dataKey:panelKey,groups:[panelGroup],spinner:false,visible:false});if(!flyoutDebug){var mouseout=mouseOutUtility();mouseout.add(flyout.elem());mouseout.action(function(){panel.hide();});mouseout.enable();} var a11y=a11yHandler({link:$link,onEscape:function(){panel.hide();$link.focus();}});var logPanelInteraction=function(promoID,wlTriggers){var logNow=$F.once().on(function(){var panelEvent=$.extend({},event,{id:promoID});if(config.browsePromos&&!!config.browsePromos[promoID]){panelEvent.bp=1;} logEvent(panelEvent);phoneHome.trigger(wlTriggers);});if(panel.isVisible()&&panel.hasInteracted()){logNow();}else{panel.onInteract(logNow);}};panel.onData(function(data){renderPromo(data.promoID,panel.elem());logPanelInteraction(data.promoID,data.wlTriggers);});panel.onShow(function(){var columnCount=$('.nav-column',panel.elem()).length;panel.elem().addClass('nav-colcount-'+columnCount);showParent();var $subCatLinks=$('.nav-subcat-links > a',panel.elem());var length=$subCatLinks.length;if(length>0){var firstElementLeftPos=$subCatLinks.eq(0).offset().left;for(var i=1;i'+ catTitle+'');panel.elem().prepend($subPanelTitle);}} $link.addClass('nav-active');});panel.onHide(function(){$link.removeClass('nav-active');hideParent();a11y.disable();sloppyTrigger.disable();});panel.onShow(function(){a11y.elems($('a, area',panel.elem()));});sloppyTrigger.register($link,panel);if(flyoutDebug){$link.click(function(){if(panel.isVisible()){panel.hide();}else{panel.show();}});} var panelKeyHandler=onKey($link,function(){if(this.isEnter()||this.isSpace()){panel.show();}},'keydown',false);$link.focus(function(){panelKeyHandler.bind();}).blur(function(){panelKeyHandler.unbind();});panel.elem().appendTo($parent);};var hideParentAndResetTrigger=function(){hideParent();sloppyTrigger.disable();};for(var i=0;i

Enter your mobile number or email address below and we'll send you a link to download the free Kindle App. Then you can start reading Kindle books on your smartphone, tablet, or computer - no Kindle device required.

ISBN-13: 978-0029290408

ISBN-10: 0029290406

This bar-code number lets you verify that you're getting exactly the right version or edition of a book. The 13-digit and 10-digit formats both work.

Read more:
Amazon.com: Science And Human Behavior (9780029290408): B ...

Cell physiology | definition of Cell physiology by Medical …

physiology[fize-olo-je]

1. the science that treats of the functions of the living organism and its parts, and of the physical and chemical factors and processes involved.

2. the basic processes underlying the functioning of a species or class of organism, or any of its parts or processes.

cell physiology the scientific study of phenomena involved in cell growth and maintenance, self-regulation and division of cells, interactions between nucleus and cytoplasm, and general behavior of protoplasm.

morbid physiology (pathologic physiology) the study of disordered functions or of function in diseased tissues.

The science concerned with the normal vital processes of animal and vegetable organisms, especially as to how things normally function in the living organism rather than to their anatomic structure, their biochemical composition, or how they are affected by drugs or disease.

[L. or G. physiologia, fr. G. physis, nature, + logos, study]

1. the science which treats of the functions of the living organism and its parts, and of the physical and chemical factors and processes involved.

2. the basic processes underlying the functioning of a species or class of organism, or any of its parts or processes.

morbid physiology, pathologic physiology the study of disordered function or of function in diseased tissues.

1. The biological study of the functions of living organisms and their parts.

2. All the functions of a living organism or any of its parts.

physiologist n.

Etymology: Gk, physis + logos, science

1 the study of the processes and function of the human body.

The science concerned with the normal vital processes of animal and vegetable organisms, especially as to how things normally function in the living organism rather than as to their anatomic structure, their biochemical composition, or how they are affected by drugs or disease.

[L. or G. physiologia, fr. G. physis, nature, + logos, study]

n in biological sciences, study concerned with the processes and functioning of organisms.

Science concerned with normal vital processes of organisms, especially as to how things normally function in living organism rather than to their anatomic structure.

[L. or G. physiologia, fr. G. physis, nature, + logos, study]

n the study of tissue and organism behavior. The physiologic process is a dynamic state of tissue as compared with the static state of descriptive morphology (anatomy). Physiology is differentiated from descriptive morphology by the following qualifying properties: rate, direction, and magnitude. Physiologic processes are thus morphologic alterations in the three dimensions of space associated with a temporary (time) sequence. Physiologic processes relate to a wide spectrum of life activities on three levels: biochemical and biophysical activity of a subcellular nature, the activity of cells and tissues aggregated into organ systems, and multiorgan system activity as expressed in human behavior.

n the physiology related to clinical manifestations in the normal and abnormal behavior of oral structures. The principal clinical functions in which the oral structures participate are deglutition, mastication, respiration, speech, and head posture.

1. the science which deals with the functions of the living organism and its parts, and of the physical and chemical factors and processes involved.

2. the basic processes underlying the functioning of a species or class of organism, or any of its parts or processes.

the scientific study of phenomena involved in cell growth and maintenance, self-regulation and division of cells, interactions between nucleus and cytoplasm, and general behavior of protoplasm.

the study of disordered functions or of function in diseased tissues.

Read this article:
Cell physiology | definition of Cell physiology by Medical ...

Sexual Behavior in the Human Male: Alfred C. Kinsey …

These three reprinted books contain most of the published statistical data taken from the original interview schedules used by Alfred Kinsey and his colleagues from 1938 to 1963 to gather sexual histories. Except for two topically focused books published by other authors after Kinsey's death, the ideas and data in these books represent the bulk of Kinsey's intellectual and empirical contribution to sex research. It is appropriate that they be reprinted in 1998, the 50th anniversary of the original publication of Sexual Behavior in the Human Male. It was with this first book that knowledge about sexuality garnered from a scientific survey burst into the consciousness of the American public. This book and its companion, Sexual Behavior in the Human Female, published in 1953, introduced a new way of thinking and talking about sexuality to American (and world) culture.

The practice of sexuality was quite varied in the United States before the publication of these books, but it was largely unrecorded, at least by scientists. Before the late 1940s, the sexual lives of most people were shaped by personal experiments, isolated sexual encounters, uninformed gossip, media sensation, and moral condemnation (not necessarily in that order). The national myth was that most people were obedient to a traditional set of sexual rules and those who were not were relatively rare and defective in morals or willpower.

It was against this background of repression and prurience that Kinsey asserted the right of science to speak about sexual behavior. As a scientist, Kinsey spoke and wrote plainly, using language about sexuality that was rarely heard or read at the time. The facts reported in the book on men's sexual behavior were at fundamental variance with the myths. Kinsey reported that the practice of masturbation was nearly universal among men (90 percent did it), that homosexual relations were widely experienced (37 percent had done it once), that premarital sexual relations were common (most college men did it), that half of married men had had extramarital sexual relations, and that oral sex was routine in deed if not in public discourse (70 percent of educated husbands said they and their wives had done it).

But it was not only these facts that evoked a powerful negative response from traditional figures in churches, legislatures, and the press. The book also had a strong reformist tone, with Kinsey arguing, completely in the American grain, that progress in dealing with sexual problems could only be made by objectively uncovering the facts of sexual life. That the reported sexual practices of American men differed from moral expectations was (in Kinsey's interpretation) evidence of the power of sexuality and not a mark of moral decay. The problems associated with sexuality were a consequence of social repression, not inherent to sexuality itself.

The controversy engendered by this first book caused Kinsey's second book, Sexual Behavior in the Human Female, to be eagerly anticipated by his critics, his defenders, the media, and the public. Its publication in 1953 was met with an equal if not greater storm than the publication of the book on men. Kinsey's evidence suggested that women were less behaviorally active than men in all aspects of sexual life but that they were still more sexual than traditional views allowed. However, the focus of the media on the statistical findings about sexual practices among women (what we now treat as "factoids") made the second book appear entirely similar to the first (by this time both books had become fused in the public mind and in the media as the "Kinsey Reports").

Contrary to this view, it is evident from a careful reading of the book on women that Kinsey had moved from his thinking in the book on men to a more nuanced view of sexuality. The book on men is severely masculinist in its perspective, using men's sexual lives as the primary model for what is considered to be sexually normal. The sexuality of the human male was characterized by novelty in practices, variety in partners, a quick and urgent response to sexual stimuli, and a search for orgasm as the primary source of sexual pleasure. Sexual Behavior in the Human Female, based on approximately 6000 interviews, is a retreat, at least in part, from all of these assumptions. Two important changes in Kinsey's thinking are apparent: women and men are more alike in the biology of their sexuality than he had previously thought, and women's sexuality and, on suitable reflection, men's sexuality seemed shaped, not merely repressed, by social and cultural forces. Increasingly, it was clear that the two books were works of social science, not biology.

The negative reaction to Kinsey and his works in the 1950s frightened off providers of funding and researchers in the field of sex research. As a consequence, the Kinsey studies were used as flawed report cards on sexual life in the United States well into the era of AIDS. The studies were particularly deficient in their sampling methods, and it was obvious to researchers at the time that they did not accurately measure the sexual life of American women and men. As science, they were important first steps but incomplete in scope and method. The findings were limited to white, better educated, less religious, and largely youthful women and men from the northeastern United States who volunteered to be interviewed about their sexual lives. We now know that the effect of volunteer respondents was to inflate the reported levels of some aspects of sexual behavior. The interview schedule and the interviewing were of high quality, but they could not correct for biases in sampling.

A proper historical understanding of Kinsey's purposes should focus on his explicit desire to understand sexuality by using objective tools of science and on his scarcely concealed desire to reform what he saw as the repressive character of sexual life in the United States during the period before the Second World War. This goal of sexual reform was scarcely unique to Kinsey -- only his scientific methods and the connection he made between science and sexual reform were special. The findings from Kinsey's work and the attitudes the work expressed quickly filtered into reformist groups that strove to change laws about sexual behavior, to free public speech about sexuality, to advance family planning through birth control, to promote sex education, and to reduce what they saw as hypocrisy about sexuality in American culture.

The association of Kinsey with sexual reform has recently made him the target, both as a scientist and a man, of attacks by conservative groups. John Bancroft, the current director of the institute that Kinsey founded, has written a spirited and important defense of Kinsey in the introduction to the reprinted edition of Sexual Behavior in the Human Female.

The third reprinted book is quite different from the other two, but it emphasizes the continuing utility to historians of the entire collection of Kinsey's interviews. This book presents the marginal tabulations of all of the interviews gathered by Kinsey and his colleagues (including those conducted after Kinsey's death in 1956) and makes them more useful by excluding certain groups that surely skewed the findings of the original report on men. Funding from the National Institute of Mental Health in the early 1960s presented an opportunity for all the 17,500 original interviews to be placed on computer tape. Of these interviews, 14,000 are treated as a "basic" sample of persons who were noncriminal; those of persons with criminal histories are treated separately. In addition, a separate sample of persons with extensive homosexual histories was selected from both the criminal and basic samples.

Kinsey and his works are now part of the story of the "American Century." Sensitive use of the archived interviews by historians as well as Kinsey's own life and views may offer us further insight into the sexual aspects of that story and the ways in which our sexual past has shaped our sexual present.

Reviewed by John Gagnon, Ph.D.

Read this article:
Sexual Behavior in the Human Male: Alfred C. Kinsey ...

Masters in Neuroscience | Neuroscience Masters Programs

Masters in Neuroscience programs prepare students to conduct, analyze and communicate critical research on the human brain and nervous system. As a sub-field of biology, Neuroscience is an interdisciplinary science that examines the structure, evolution and functioning of the nervous system in relation to behavioral patterns. It draws from a spectrum of other fields that includes biology, chemistry, physics, linguistics, math, computer science and philosophy, which could contribute to your Masters in Neuroscience.

Masters in Neuroscience programs provide additional and intensive laboratory research and academic training to students who have completed an undergraduate major in neuroscience or a closely related scientific area, and wish to extend their studies before moving on toa Ph.D. research program or professional employment. Physicians who are seeking to expand their expertise about the nervous system may also benefit from a Masters degree in Neuroscience.

Prerequisite educationfor a Masters of Neuroscience degree is a Bachelorsdegree in physical, behavioral or biological science; a strong background in math and physics is also recommended. There are both thesis and non-thesis options; students who prefer to enter the workforce upon graduation may take a non-thesis master's program.

GradSchools.com makes it easy to find Neuroscience Masters Programsby learning format. If you prefer traditional on-campus learning, you may want to initiate a search by location; use the city, state or country tabs to browse listings. If distance-learning is more convenient to you, look into online masters in neuroscience degrees. Some of the choices might include MS Cognitive and Computational Neuroscience, or Master of Science in Neuroscience.

Each Masters of neuroscience degree program may have its own specific course requirements.

Some programs may include elements of biology, statistics, physiology and pharmacology. Curricula tend to be lab-intensive, and students have the opportunity to develop their analytical science skills in addition to their general competence in neuroscience and its sub-areas. Some of the common course topics students might expect to encounter may include:

Students may decide to specialize in a wide variety of areas. Some potential concentrations might include:

Graduates of master's programs in neuroscience may pursue a variety of potential career opportunities in diverse areas, though level of education may matter; if your ultimate goal is to become a medical scientist, neurologist, academic, or higher-level researcher, an MS in Neuroscience is a springboard, rather than a qualifying degree.

This being said, employment growth for Neurology technicians, which is included in the category of Medical and Clinical Laboratory Technologists and Technicians is projected to increase by 16% between 2014 and 2024. The Bureau of Labor Statistics considers this much faster than average growth.[i]Other potential careers might include:

Neurogenetic Counselors.: According to the BLS, more genetic counselors are specializing in fields such as cardiovascular health, genomic medicine, neurogenetics, and psychiatry, and employment of genetic counselors is projected to grow 29% from 2014 to 2024[ii]

Neuropsychologists: Study the effects of brain injuries, brain disease, developmental disorders, or mental health conditions on behavior and thinking. Employment growth for Psychologists is also favorable; a 19% growth is projected between 2014 and 2024[iii]

Earning a Masters in Neuroscience is a degree that has the potential to prepare you to either enter the workforce upon graduation, or pursue higher education and thus open yourself to other professional options. Why not begin reviewing the Neuroscience Masters Programson GradSchool.com to find one that aligns with your goals!

Sources: [i] bls.gov/ooh/life-physical-and-social-science/medical-scientists.htm | [ii] bls.gov/ooh/healthcare/genetic-counselors.htm | [iii] bls.gov/ooh/life-physical-and-social-science/psychologists.htm | bls.gov/ooh/healthcare/medical-and-clinical-laboratory-technologists-and-technicians.htm

Read more:
Masters in Neuroscience | Neuroscience Masters Programs

Portal:Neuroscience – Wikipedia

Major depressive disorder (also known as clinical depression, major depression, unipolar depression, or unipolar disorder) is a mental disorder typically characterized by a pervasive low mood, low self-esteem, and loss of interest or pleasure in usual activities. The term was selected by the American Psychiatric Association for the 1980 version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) classification for the symptom cluster, and has become widely used since. The general term depression is often used to describe the disorder, but since it is also used to describe temporary sadness or a depressed mood, more precise terminology is preferred in clinical use and research. Major depression is an often disabling condition which adversely affects a person's family, work or school life, sleeping and eating habits, and general health. In the United States around 3.4% of people with major depression commit suicide, and up to 60% of all people who commit suicide have depression or another mood disorder.

The diagnosis of major depressive disorder is based on the patient's self-reported experiences, behavior reported by relatives or friends, and mental state. There is no laboratory test for major depression, although physicians generally request tests for physical conditions that may cause similar symptoms. The most common time of onset is between the ages of 30 and 40 years, with a later peak between 50 and 60 years. Major depression occurs about twice as frequently in women as in men, although men are at higher risk for suicide.

Most patients are treated in the community with antidepressant medication and supportive counseling, and some with psychotherapy. Admission to hospital may be necessary in cases associated with self-neglect or a significant risk of harm to self or others. A minority with severe illness may be treated with electroconvulsive therapy (ECT), under a short-acting general anaesthetic. The course of the disorder varies widely, from a once-only occurrence lasting months to a lifelong disorder with recurrent major depressive episodes. Depressed individuals have a shorter life expectancy than those without depression, being more susceptible to medical conditions such as heart disease. Sufferers and former patients may be stigmatized.

The understanding of the nature and causes of depression has evolved over the centuries; nevertheless, many aspects of depression are still not fully understood, and are the subject of debate and research. Psychological, psycho-social, evolutionary and biological causes have been proposed. Psychological treatments are based on theories about personality, interpersonal communication, and unduly negative thoughts. The monoamine chemicals serotonin, norepinephrine, and dopamine are naturally present in the brain and assist communication between nerve cells. Monoamines have been implicated in depression, and most antidepressants work to increase the active levels of at least one.

Originally posted here:
Portal:Neuroscience - Wikipedia

Atossa Genetics Announces Second Quarter 2018 Financial …

SEATTLE, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced second quarter ended June 30, 2018 financial results and provided an update on recent company developments.

Steve Quay, President and CEO commented, We have made tremendous progress with our clinical programs. We opened enrollment in two phase 2 clinical studies: one study using our proprietary topical Endoxifen for breast density reduction, and another study using our proprietary oral Endoxifen for reducing breast cancer tumor cell activity in the window of opportunity between diagnosis of breast cancer and surgery. We also completed dosing and patient visits in our phase 1 study of topical Endoxifen in men. Our intraductal microcatheter immunoOncology pre-clinical program was launched and we contracted with an additional manufacturer for Endoxifen. We have had a very busy and productive first six months of 2018 as we continue the momentum in the advancement of our clinical programs. We are looking forward to announcing preliminary results from our phase 1 study of topical Endoxifen in men by September 30, 2018, added Dr. Quay.

Recent Corporate Developments

Atossas important recent developments include the following:

Q2 2018 Financial Results

For the three and six months ended June 30, 2018 and 2017, we had no revenue and no associated cost of revenue.

Total operating expenses were approximately $4.1 million and $6.0 million for the three and six months ended June 30, 2018, respectively, consisting of general and administrative (G&A) expenses of approximately $2.7 million and $4.1 million, respectively; and research and development (R&D) expenses of approximately $1.5 million and $1.9 million, respectively. For the previous year, total operating expenses were approximately $1.9 million and $3.6 million for the three and six months ended June 30, 2017, respectively, consisting of G&A expense of approximately $1.1 million and $2.2 million, respectively, and R&D expenses of $0.8 million and $1.4 million, respectively.

About Atossa Genetics

Atossa Genetics Inc., is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit http://www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossas drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact:

Atossa Genetics Inc.Kyle GuseCFO and General CounselOffice: 866 893-4927kyle.guse@atossagenetics.com

Investor Relations Contact:

Scott GordonCorProminence LLC377 Oak StreetConcourse 2Garden City, NY 11530Office: (516) 222-2560scottg@corprominence.com

Source: Atossa Genetics Inc.

Read more:
Atossa Genetics Announces Second Quarter 2018 Financial ...

Understanding genetic architecture of different traits and …

ByRobin Scullin

Scientists at Johns Hopkins Bloomberg School of Public Health have developed a powerful method for characterizing patterns of genetic contributions to different traits such as height, BMI, and childhood IQ, as well as diseases including Alzheimer's disease, diabetes, heart disease, and bipolar disorder. The new method provides a "big picture" of genetic influences that should be particularly helpful in designing future genetic studies and understanding genetic risk prediction.

In a study published today in the journal Nature Genetics, the scientists mined existing data from genetic studies and used novel statistical techniques to obtain estimates of the numbers of DNA variations that contribute to different physical traits and diseases,

"In terms of practical results, we can now use this method to estimate, for any trait or disease, the number of individuals we need to sample in future studies to identify the majority of the important genetic contributions," says study senior author Nilanjan Chatterjee, a Bloomberg Distinguished Professor in the Department of Biostatistics.

Bloomberg Distinguished Professor in Department of Biostatistics

Affordable DNA-sequencing technology became available around the turn of the millennium. With it, researchers have performed hundreds of genome-wide association studies to discover DNA variations that are linked to different diseases or traits. These variationscalled single nucleotide polymorphisms, or SNPsare changes in DNA "letters" at various sites on the genome. Knowing which variations are linked to a disease or trait can be useful in gaining biological understanding about how diseases and other traits originate and further progress.

There is also interest in using genetic markers to develop risk-scores that could identify individuals at high or low risk for diseases and then use the information to develop a "precision medicine" approach to disease prevention.

"Depending on their sample sizes, previous genome-wide association studies have uncovered a few SNPs or many for any given disease or trait," Chatterjee says. "But what they generally haven't done is reveal the overall genetic architectures of diseases or traitsin other words, the likely number of SNPs that contribute and the distributions of their effect sizes."

Chatterjee and his colleagues developed statistical tools to infer this overall architecture from publicly available genome-wide association study data. They then applied these tools to 32 datasets covering 19 quantitative traits and 13 diseases.

The findings show that what is known about many traits represents the "tip of the iceberg." An individual trait could be associated with thousands to tens of thousands of SNPs, each of which has small effect, but which cumulatively make a substantial contribution to the trait variation. Intriguingly, they found that traits related to mental health and ability, such as IQ, depression, and schizophrenia, appear to be influenced by the largest number, on the order of tens of thousands of SNPs, each with tiny effects.

"For the traits we analyzed related to mental health and cognitive ability, there is really a continuum of effect sizes, suggesting a distinct type of genetic architecture," says Chatterjee, who has a joint appointment in Johns Hopkins Medicine's Department of Oncology.

By contrast, the analysis suggested that common chronic diseases such as heart disease and type-2 diabetes typically are influenced by relatively feweron the order of thousandsof SNPs, most of which have small effects, although a sizable group "stick out" for their stronger effects.

Knowing the approximate genetic architecture of a disease or trait allows scientists to predict how informative any new genome-wide association studies for that trait or disease will be, given the sample size. For example, projections in the study suggest that for most traits and diseases, such as heart disease and diabetes, the point of diminishing return for these studies only starts after a sample size reaches several hundred thousand. For psychiatric diseases and cognitive traits, with their "long-tail" distributions of gene effects, diminishing returns usually won't kick in until sample sizes are even larger‐possibly in the millions, Chatterjee says. These results have implications for how useful genetic risk prediction models could be for different diseases depending on the sample size achievable for future studies.

"Our approach at least provides the best available 'road map' of what is needed in future studies," Chatterjee says.

See the original post here:
Understanding genetic architecture of different traits and ...

The comparative and genetic methods for East European …

Taxonomy of freshwater mussels from family Unionidae has been ambiguous for a long time. A number of methods used for their identification, including the so-called comparative method, are based on shell morphology. However, this morphology turned out to have a high level of within-species variation, and the shape of the shell of a specimen depends strongly on its environment and conditions of growth. For these reasons, the number of species recognized by the comparative method kept increasing. We applied both the comparative morphological method and methods of molecular genetics to address the taxonomy of Unionidae. We performed the comprehensive study of 70 specimens of Unionidae mussels collected from the River Ivitza, Volga basin. The specimens represented 14 comparative species, belonging to 4 comparative genera of Unionidae: Colletopterum, Pseudanodonta, Unio and Crassiana. Sequencing of the nuclear (ITS1) and mitochondrial (COI, 16S rDNA) genetic regions revealed 5 groups with high within-group genetic homogeneity separated from each other by long genetic distances. According to the comparison with the available sequences, these groups correspond to 3 Eastern European genera and 5 species: Anodonta anatina, Pseudanodonta complanata, Unio pictorum, Unio tumidus and Unio crassus. The results obtained indicate that the comparative method is inappropriate for the taxonomic analysis of East European Unionidae.

More:
The comparative and genetic methods for East European ...

Analysts See $-0.13 EPS for Cancer Genetics, Inc. (CGIX …

August 13, 2018 - By Kristin Houston

Investors sentiment increased to 1.11 in Q1 2018. Its up 0.20, from 0.91 in 2017Q4. It improved, as 3 investors sold Cancer Genetics, Inc. shares while 6 reduced holdings. 6 funds opened positions while 4 raised stakes. 2.70 million shares or 2.75% less from 2.78 million shares in 2017Q4 were reported.The Illinois-based Northern Tru Corporation has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Morgan Stanley holds 16,169 shares or 0% of its portfolio. Geode Limited Liability has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). 11,600 were accumulated by Spark Invest Management Ltd Llc. Perkins Cap Management reported 963,600 shares. Virtu Financial Ltd Liability Corporation accumulated 0% or 29,495 shares. Granahan Inv Ma owns 235,502 shares. Wells Fargo Mn reported 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). National Bank Of America Corporation De has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Barclays Public Limited Company has invested 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX). Moreover, Jacobs Levy Equity Management Incorporated has 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX). The New York-based Hrt Lc has invested 0.02% in Cancer Genetics, Inc. (NASDAQ:CGIX). Vanguard Group Inc holds 583,886 shares or 0% of its portfolio. Dimensional Fund Advsr Limited Partnership reported 19,866 shares. Diker Mngmt Ltd Liability invested 0.04% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX).

Analysts expect Cancer Genetics, Inc. (NASDAQ:CGIX) to report $-0.13 EPS on August, 14 before the open.They anticipate $0.03 EPS change or 18.75 % from last quarters $-0.16 EPS. After having $-0.16 EPS previously, Cancer Genetics, Inc.s analysts see -18.75 % EPS growth. The stock decreased 3.22% or $0.0314 during the last trading session, reaching $0.9451. About 69,965 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has declined 74.25% since August 13, 2017 and is downtrending. It has underperformed by 86.82% the S&P500.

Among 2 analysts covering Cancer Genetics (NASDAQ:CGIX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Cancer Genetics had 3 analyst reports since April 3, 2018 according to SRatingsIntel. The firm earned Hold rating on Tuesday, April 3 by Maxim Group. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) has Buy rating given on Tuesday, May 29 by H.C. Wainwright. The company was maintained on Wednesday, June 27 by H.C. Wainwright.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $26.22 million. The Companys tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

More news for Cancer Genetics, Inc. (NASDAQ:CGIX) were recently published by: Nasdaq.com, which released: Cancer Genetics to Report Second Quarter 2018 Financial Results on August 14, 2018 on August 07, 2018. Globenewswire.coms article titled: Cancer Genetics Closes $2.625 million Convertible Note Financing and published on July 18, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Link:
Analysts See $-0.13 EPS for Cancer Genetics, Inc. (CGIX ...

Immunology: With STUDENT CONSULT Online Access (Immunology …

').appendTo(flyout.elem());var panelGroup=flyout.getName()+'SubCats';var hideTimeout=null;var sloppyTrigger=createSloppyTrigger($parent);var showParent=function(){if(hideTimeout){clearTimeout(hideTimeout);hideTimeout=null;} if(visible){return;} var height=$('#nav-flyout-shopAll').height(); $parent.css({'height': height});$parent.animate({width:'show'},{duration:200,complete:function(){$parent.css({overflow:'visible'});}});visible=true;};var hideParentNow=function(){$parent.stop().css({overflow:'hidden',display:'none',width:'auto',height:'auto'});panels.hideAll({group:panelGroup});visible=false;if(hideTimeout){clearTimeout(hideTimeout);hideTimeout=null;}};var hideParent=function(){if(!visible){return;} if(hideTimeout){clearTimeout(hideTimeout);hideTimeout=null;} hideTimeout=setTimeout(hideParentNow,10);};flyout.onHide(function(){sloppyTrigger.disable();hideParentNow();this.elem().hide();});var addPanel=function($link,panelKey){var panel=dataPanel({className:'nav-subcat',dataKey:panelKey,groups:[panelGroup],spinner:false,visible:false});if(!flyoutDebug){var mouseout=mouseOutUtility();mouseout.add(flyout.elem());mouseout.action(function(){panel.hide();});mouseout.enable();} var a11y=a11yHandler({link:$link,onEscape:function(){panel.hide();$link.focus();}});var logPanelInteraction=function(promoID,wlTriggers){var logNow=$F.once().on(function(){var panelEvent=$.extend({},event,{id:promoID});if(config.browsePromos&&!!config.browsePromos[promoID]){panelEvent.bp=1;} logEvent(panelEvent);phoneHome.trigger(wlTriggers);});if(panel.isVisible()&&panel.hasInteracted()){logNow();}else{panel.onInteract(logNow);}};panel.onData(function(data){renderPromo(data.promoID,panel.elem());logPanelInteraction(data.promoID,data.wlTriggers);});panel.onShow(function(){var columnCount=$('.nav-column',panel.elem()).length;panel.elem().addClass('nav-colcount-'+columnCount);showParent();var $subCatLinks=$('.nav-subcat-links > a',panel.elem());var length=$subCatLinks.length;if(length>0){var firstElementLeftPos=$subCatLinks.eq(0).offset().left;for(var i=1;i'+ catTitle+'');panel.elem().prepend($subPanelTitle);}} $link.addClass('nav-active');});panel.onHide(function(){$link.removeClass('nav-active');hideParent();a11y.disable();sloppyTrigger.disable();});panel.onShow(function(){a11y.elems($('a, area',panel.elem()));});sloppyTrigger.register($link,panel);if(flyoutDebug){$link.click(function(){if(panel.isVisible()){panel.hide();}else{panel.show();}});} var panelKeyHandler=onKey($link,function(){if(this.isEnter()||this.isSpace()){panel.show();}},'keydown',false);$link.focus(function(){panelKeyHandler.bind();}).blur(function(){panelKeyHandler.unbind();});panel.elem().appendTo($parent);};var hideParentAndResetTrigger=function(){hideParent();sloppyTrigger.disable();};for(var i=0;i

Enter your mobile number or email address below and we'll send you a link to download the free Kindle App. Then you can start reading Kindle books on your smartphone, tablet, or computer - no Kindle device required.

ISBN-13: 978-0323080583

ISBN-10: 0323080588

This bar-code number lets you verify that you're getting exactly the right version or edition of a book. The 13-digit and 10-digit formats both work.

Read the original here:
Immunology: With STUDENT CONSULT Online Access (Immunology ...